What is the 13F Pro Quality Score for SBFM?

13F Pro ranks Sunshine Biopharma Inc. (SBFM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SBFM's current score at https://13fpro.ai/research/SBFM (free sign-up required for the full ranking).

Which hedge funds own the most SBFM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SBFM include CITADEL ADVISORS, TWO SIGMA SECURITIES,, XTX Topco Ltd. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SBFM as soon as new 13F filings post.

Where does 13F Pro source SBFM data?

All Sunshine Biopharma Inc. fundamentals and ownership data come directly from SEC EDGAR. Sunshine Biopharma Inc. files with the SEC under CIK 1402328. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SBFM in?

Sunshine Biopharma Inc. (SBFM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SBFM research updated on 13F Pro?

SBFM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sunshine Biopharma Inc.(SBFM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1402328 SBFM stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $36.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SBFM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Sunshine Biopharma Inc. (SBFM), a Healthcare sector company. SBFM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $36.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Sunshine Biopharma Inc. reports quarterly revenue of $8.1M, net income of $-1.2M, an operating margin of -17.3%. Top institutional holders of SBFM by reported 13-F value include CITADEL ADVISORS, TWO SIGMA SECURITIES,, XTX Topco Ltd, based on the most recent SEC filings. SBFM trades on the Nasdaq exchange and files with the SEC under CIK 1402328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SBFM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sunshine Biopharma Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$8.1M

Net Income

Q1 2026

$-1.2M

Free Cash Flow

Q1 2026

$-2.1M

Operating Margin

Q1 2026

-17.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+4.1% YoY

$36.3MFY 2025

FY22 $4.3MFY23 $24.1MFY24 $34.9MFY25 $36.3M

Net Income

-16.4% YoY

$-6.0MFY 2025

FY22 $-26.7MFY23 $-4.5MFY24 $-5.1MFY25 $-6.0M

Operating Income

-7.1% YoY

$-6.2MFY 2025

FY22 $-27.0MFY23 $-4.8MFY24 $-5.8MFY25 $-6.2M

EPS (Diluted)

—FY 2025

FY22 $-0.25FY23 $-49.49FY24 $-7.32FY25 —

Total Assets

-1.6% YoY

$30.1MFY 2025

FY22 $29.2MFY23 $27.3MFY24 $30.6MFY25 $30.1M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+57.4% YoY

$-5.3MFY 2025

FY22 $-5.2MFY23 $-8.8MFY24 $-12.5MFY25 $-5.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$36.3M +4.1%	$34.9M +44.7%	$24.1M +454.4%	$4.3M +1802.4%	$228.4K +219.9%	$71.4K
Net Income	$-6.0M -16.4%	$-5.1M -13.9%	$-4.5M +83.2%	$-26.7M -115.0%	$-12.4M -346.7%	$-2.8M
Operating Income	$-6.2M -7.1%	$-5.8M -21.5%	$-4.8M +82.3%	$-27.0M -1006.5%	$-2.4M -323.0%	$-576.9K
EPS (Diluted)	—	$-7.32 +85.2%	$-49.49 -19862.6%	$-0.25 +63.0%	$-0.67	—
Total Assets	$30.1M -1.6%	$30.6M +11.8%	$27.3M -6.5%	$29.2M +1227.5%	$2.2M +110.7%	$1.0M
Total Debt	—	—	—	—	—	$949.0K
Operating Cash Flow	$-5.3M +57.4%	$-12.5M -42.7%	$-8.8M -67.2%	$-5.2M -186.9%	$-1.8M -178.3%	$-657.3K

AI Insight: SBFM Financial Trends

Sunshine Biopharma remains unprofitable with flat-to-declining revenue at $8–10M quarterly; no clear path to profitability visible.

• Revenue averaged $9M across eight quarters (Q2 2024–Q1 2026) with no sustained growth; latest quarter at $8M marks low end.

• Operating cash flow persistently negative, ranging $1M–$5M burn per quarter; Q1 2026 at $2M negative.

• Net losses consistent at $1–$2M per quarter; cumulative $12M loss over eight quarters on $73M cumulative revenue.

⚠ Equity base stable $22–26M range despite ongoing losses; balance sheet deterioration risk if burn rate accelerates.

⚠ No debt disclosed across all periods; dependency on equity funding or asset depletion to fund operations.

AI Insight: SBFM Ratio Trends

Sunshine Biopharma remains deeply unprofitable across all metrics, with no sustained improvement trajectory and deteriorating TTM profitability.

• Operating margin worsened to -17.2% in Q1 2026 from -11.5% in Q3 2025, reversing prior-quarter improvement.

• TTM operating margin stands at -17.8%, net profit margin at -17.0%, reflecting consistent cash burn.

• ROE and ROA remain severely negative (TTM: -28.1% and -21.6%), with no path to profitability visible in data.

⚠ Q4 periods (2024, 2025) show material margin deterioration; Q1 2026 weakness suggests seasonality or structural challenge.

⚠ ROIC at -25.9% (Q1 2026) vs -18.0% (Q3 2025) signals capital destruction accelerating in latest quarter.

Get alerted when SBFM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sunshine Biopharma Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SBFM

CITADEL ADVISORS LLC
$48.1K46,248 sh
TWO SIGMA SECURITIES, LLC
$24.4K23,482 sh
XTX Topco Ltd
$22.3K21,457 sh
MORGAN STANLEY
$15.2K14,634 sh
COMMONWEALTH EQUITY SERVICES, LLC
$14.0K13,437 sh
SBI Securities Co., Ltd.
$1.9K1,834 sh
UBS Group AG
$1.8K23,879 sh
UBS Group AG
$1.1K1,103 sh
NATIONAL BANK OF CANADA /FI/
$9.009 sh
OSAIC HOLDINGS, INC.
$2.002 sh

Fund	Value	Shares
CITADEL ADVISORS LLC	$48.1K	46,248
TWO SIGMA SECURITIES, LLC	$24.4K	23,482
XTX Topco Ltd	$22.3K	21,457
MORGAN STANLEY	$15.2K	14,634
COMMONWEALTH EQUITY SERVICES, LLC	$14.0K	13,437
SBI Securities Co., Ltd.	$1.9K	1,834
UBS Group AG	$1.8K	23,879
UBS Group AG	$1.1K	1,103
NATIONAL BANK OF CANADA /FI/	$9.00	9
OSAIC HOLDINGS, INC.	$2.00	2

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SBFM on your watchlist

Track score changes the day Sunshine Biopharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SBFM a good stock to buy?

13F Pro's AI-powered analysis of Sunshine Biopharma Inc. (SBFM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SBFM are available on the SBFM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SBFM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SBFM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sunshine Biopharma Inc.'s investment landscape.